Researchers conducted this multicentre, randomized, placebo‐controlled trial to evaluate the effectiveness, safety, and tolerability of oromucosal nabiximols cannabinoid medicine as adjunct therapy for children with spasticity due to cerebral palsy/traumatic central nervous system injury with inadequate response to existing treatment. In total, 72 individuals (mean [SD] age 12y 4mo [3y 1mo], range 8‒18y) were randomized at a ratio of 2:1 to receive nabiximols (= 47; 29 males, 18 females) or placebo (= 25; 15 males, 10 females) for 12 weeks (12 sprays/day max. based on clinical response/tolerability). Paediatric patients usually respond well to oromucosal nabiximols.

Three cases of hallucinations, one of which involved auditory hallucinations and a suicide attempt, were however observed. Oromucosal nabiximols compared with placebo did not minimize cerebral palsy/central nervous system injury‐related spasticity.

Original Article: https://www.mdlinx.com/journal-summaries/cerebral-palsy-cp-traumatic-brain-injury/2020/04/30/7673330/?spec=neurology